AC Immune Third Quarter 2026 Financial and Corporate Update
Key Highlights
- ➤ACI-7104 received FDA Fast Track designation and IND clearance.
- ➤ACI-7104 showed 100% immunogenicity response after three immunizations in Phase 2.
- ➤ACI-19764 was safe and well-tolerated with confirmed CSF penetration in Phase 1.
- ➤Cash resources CHF 73.9 million, funding operations into Q1 2028.
- ➤Q3 revenue CHF 3.2 million; net loss narrowed to CHF 8.8 million.
Expert Statements
Martin Zügel, Interim CEO of AC Immune SA
“This quarter was an important period for AC Immune as we saw our pipeline of wholly-owned programs delivering positive clinical results.”
Martin Zügel, Interim CEO of AC Immune SA
“Our proprietary programs targeting a-syn have seen important developments including encouraging clinical results for ACI-7104 in Parkinson’s disease and the recent nomination of a lead small-molecule Morphomer(®) candidate drug which will now be entering preclinical development.”
Martin Zügel, Interim CEO of AC Immune SA
“Together with the initial hsCRP results in the Phase 1b trial to be reported in the early part of next year, we believe we are well positioned across our portfolio moving into 2027.”
Positive clinical and regulatory progress achieved across wholly-owned pipeline * ACI-7104 received FDA Fast Track designation, Investigational New Drug (IND) clearance, and reported positive Part 1 week-100 results from the Phase 2 VacSYn trial in Parkinson’s disease * Positive interim safety and tolerability results from the Phase 1 trial of NLRP3 inhibitor ACI-19764 in healthy volunteers * Lead candidate declared in Morphomer(®) small molecule program targeting intracellular alpha-synuclein (a-syn) * Further clinical data anticipated before year-end for ACI-7104 and early in 2027 for ACI-19764 * Cash resources of CHF 73.9 million as of September 30, 2026, providing cash runway into Q1 2028 Lausanne, Switzerland, November 4, 2026 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharma company targeting the key pathologic misfolded proteins and pathways that drive neurodegenerative diseases, today provided financial and corporate updates for the quarter ended September 30, 2026.
Get started
Create a free account to read the full story.